The Challenge of Antidepressant Therapeutics in Alzheimer's Disease

Madia Lozupone; Maddalena La Montagna; Francesca D’Urso; Carla Piccininni; Angelo Rinaldi; Massimiliano Beghi; Cesare Maria Cornaggia; Rodolfo Sardone; Vincenzo Solfrizzi; Antonio Daniele; Davide Seripa; Gianluigi Giannelli; Antonello Bellomo; Francesco Panza

doi:10.1007/978-3-030-42667-5_10

The Challenge of Antidepressant Therapeutics in Alzheimer's Disease

Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, Carla Piccininni, Angelo Rinaldi, Massimiliano Beghi, Cesare Maria Cornaggia, Rodolfo Sardone, Vincenzo Solfrizzi, Antonio Daniele, Davide Seripa, Gianluigi Giannelli, Antonello Bellomo, Francesco Panza

Risultato della ricerca: Contributo in libro › Chapter

Abstract

The link between depression and Alzheimer's disease (AD) is controversial, because it is not clear if depression is an independent risk factor for the disease or a prodromal symptom in the older population. Cerebral amyloid-β (Aβ) peptide deposition is associated with both cognitive symptoms and neuropsychiatric symptoms (NPS), which may be a biological mechanism of compensation. Despite the widespread use of antidepressant therapeutics (30-50% of patients with AD/dementia are on antidepressants), there is mixed evidence regarding the benefits from their use in AD depression. Monoaminergic antidepressant drugs have shown only modest or no clinical benefits. Therefore, it is important to understand the reason of this drug-resistance and the relationship between antidepressant drugs and the Aβ peptide. The goal of the present review is to highlight the etiology of depression in patients affected by AD in comparison to depressive disorders without AD, and to speculate on more appropriate and alternative therapeutics.

Lingua originale	English
Titolo della pubblicazione ospite	Advances in Experimental Medicine and Biology
Pagine	267-281
Numero di pagine	15
Volume	1260
DOI	https://doi.org/10.1007/978-3-030-42667-5_10
Stato di pubblicazione	Pubblicato - 2020

Keywords

Alzheimer’s disease
Amyloid-β peptide
Antidepressant
Antipsychotics
Biomarkers
Depression
Mood stabilizers
Serotonin reuptake inhibitors

Accesso al documento

10.1007/978-3-030-42667-5_10

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Lozupone, M., La Montagna, M., D’Urso, F., Piccininni, C., Rinaldi, A., Beghi, M., Cornaggia, C. M., Sardone, R., Solfrizzi, V., Daniele, A., Seripa, D., Giannelli, G., Bellomo, A., & Panza, F. (2020). The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. In Advances in Experimental Medicine and Biology (Vol. 1260, pagg. 267-281) https://doi.org/10.1007/978-3-030-42667-5_10

@inbook{98fe98e31cfe46a5b1c58f30e445988f,

title = "The Challenge of Antidepressant Therapeutics in Alzheimer's Disease",

abstract = "The link between depression and Alzheimer's disease (AD) is controversial, because it is not clear if depression is an independent risk factor for the disease or a prodromal symptom in the older population. Cerebral amyloid-β (Aβ) peptide deposition is associated with both cognitive symptoms and neuropsychiatric symptoms (NPS), which may be a biological mechanism of compensation. Despite the widespread use of antidepressant therapeutics (30-50% of patients with AD/dementia are on antidepressants), there is mixed evidence regarding the benefits from their use in AD depression. Monoaminergic antidepressant drugs have shown only modest or no clinical benefits. Therefore, it is important to understand the reason of this drug-resistance and the relationship between antidepressant drugs and the Aβ peptide. The goal of the present review is to highlight the etiology of depression in patients affected by AD in comparison to depressive disorders without AD, and to speculate on more appropriate and alternative therapeutics.",

keywords = "Alzheimer{\textquoteright}s disease, Amyloid-β peptide, Antidepressant, Antipsychotics, Biomarkers, Depression, Mood stabilizers, Serotonin reuptake inhibitors, Alzheimer{\textquoteright}s disease, Amyloid-β peptide, Antidepressant, Antipsychotics, Biomarkers, Depression, Mood stabilizers, Serotonin reuptake inhibitors",

author = "Madia Lozupone and {La Montagna}, Maddalena and Francesca D{\textquoteright}Urso and Carla Piccininni and Angelo Rinaldi and Massimiliano Beghi and Cornaggia, {Cesare Maria} and Rodolfo Sardone and Vincenzo Solfrizzi and Antonio Daniele and Davide Seripa and Gianluigi Giannelli and Antonello Bellomo and Francesco Panza",

year = "2020",

doi = "10.1007/978-3-030-42667-5_10",

language = "English",

isbn = "978-3-030-42666-8",

volume = "1260",

pages = "267--281",

booktitle = "Advances in Experimental Medicine and Biology",

}

Lozupone, M, La Montagna, M, D’Urso, F, Piccininni, C, Rinaldi, A, Beghi, M, Cornaggia, CM, Sardone, R, Solfrizzi, V, Daniele, A, Seripa, D, Giannelli, G, Bellomo, A & Panza, F 2020, The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. in Advances in Experimental Medicine and Biology. vol. 1260, pagg. 267-281. https://doi.org/10.1007/978-3-030-42667-5_10

TY - CHAP

T1 - The Challenge of Antidepressant Therapeutics in Alzheimer's Disease

AU - Lozupone, Madia

AU - La Montagna, Maddalena

AU - D’Urso, Francesca

AU - Piccininni, Carla

AU - Rinaldi, Angelo

AU - Beghi, Massimiliano

AU - Cornaggia, Cesare Maria

AU - Sardone, Rodolfo

AU - Solfrizzi, Vincenzo

AU - Daniele, Antonio

AU - Seripa, Davide

AU - Giannelli, Gianluigi

AU - Bellomo, Antonello

AU - Panza, Francesco

PY - 2020

Y1 - 2020

N2 - The link between depression and Alzheimer's disease (AD) is controversial, because it is not clear if depression is an independent risk factor for the disease or a prodromal symptom in the older population. Cerebral amyloid-β (Aβ) peptide deposition is associated with both cognitive symptoms and neuropsychiatric symptoms (NPS), which may be a biological mechanism of compensation. Despite the widespread use of antidepressant therapeutics (30-50% of patients with AD/dementia are on antidepressants), there is mixed evidence regarding the benefits from their use in AD depression. Monoaminergic antidepressant drugs have shown only modest or no clinical benefits. Therefore, it is important to understand the reason of this drug-resistance and the relationship between antidepressant drugs and the Aβ peptide. The goal of the present review is to highlight the etiology of depression in patients affected by AD in comparison to depressive disorders without AD, and to speculate on more appropriate and alternative therapeutics.

AB - The link between depression and Alzheimer's disease (AD) is controversial, because it is not clear if depression is an independent risk factor for the disease or a prodromal symptom in the older population. Cerebral amyloid-β (Aβ) peptide deposition is associated with both cognitive symptoms and neuropsychiatric symptoms (NPS), which may be a biological mechanism of compensation. Despite the widespread use of antidepressant therapeutics (30-50% of patients with AD/dementia are on antidepressants), there is mixed evidence regarding the benefits from their use in AD depression. Monoaminergic antidepressant drugs have shown only modest or no clinical benefits. Therefore, it is important to understand the reason of this drug-resistance and the relationship between antidepressant drugs and the Aβ peptide. The goal of the present review is to highlight the etiology of depression in patients affected by AD in comparison to depressive disorders without AD, and to speculate on more appropriate and alternative therapeutics.

KW - Alzheimer’s disease

KW - Amyloid-β peptide

KW - Antidepressant

KW - Antipsychotics

KW - Biomarkers

KW - Depression

KW - Mood stabilizers

KW - Serotonin reuptake inhibitors

KW - Alzheimer’s disease

KW - Amyloid-β peptide

KW - Antidepressant

KW - Antipsychotics

KW - Biomarkers

KW - Depression

KW - Mood stabilizers

KW - Serotonin reuptake inhibitors

UR - http://hdl.handle.net/10807/152689

U2 - 10.1007/978-3-030-42667-5_10

DO - 10.1007/978-3-030-42667-5_10

M3 - Chapter

SN - 978-3-030-42666-8

VL - 1260

SP - 267

EP - 281

BT - Advances in Experimental Medicine and Biology

ER -

The Challenge of Antidepressant Therapeutics in Alzheimer's Disease

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo